A Prospective Observational Study of Patients Receiving Dupixent for Atopic Dermatitis

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 18 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Mar 2024 Results (N = 955; data cutoff: March 2023) assessing patient-reported outcomes, that complement clinical AD assessments and guide healthcare decision-making, and a summary of adverse events one year after dupilumab initiation presented at the American Academy of Dermatology annual Meeting 2024
12 Mar 2024 Results of dupilumab effectiveness, through physician-assessed AD clinical tools that measure disease severity over time, and a summary of adverse events in patients one year after initiating treatment, presented at the American Academy of Dermatology annual Meeting 2024
21 Mar 2023 Results assessing (n=952, data cut off March 2022) prior atopic dermatitis (AD) treatment usage in patients with AD initiating treatment with dupilumab in a real-world setting presented at the American Academy of Dermatology annual Meeting 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com